TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Nexium Study To Suppress Nausea During Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~For inclusion, participants must:~* be female, age 18 years or older~* sign an informed consent~* have Stage I, II, or III breast cancer~* be receiving at least four cycles of anthracycline-based chemotherapy which may include: doxorubicin/cyclophosphamide AC),5-fluorouracil/doxorubicin/cyclophosphamide (FAC), fluoruracil/epirubicin/cyclophosphamide (FEC) or dose dense chemotherapy regimen (AC every two weeks) as their agents for neoadjuvant or adjuvant chemotherapy~* patient must receive a serotonin receptor antagonist and a steroid for premedication~* have a negative serum pregnancy test within 7 days prior to starting study if pre-menopausal~* have adequate renal function, defined by a serum creatinine within 1.5 times the upper limit of normal~* have adequate liver function, defined by a total bilirubin, SGOT, alkaline phosphatase and albumin within 1.5 times the upper limits of normal~* have adequate bone marrow function, defined as a WBC \>4.0, platelet count \>100K, and HCT \>30~* have no prior or current malignancies for which chemotherapy was utilized~* have a performance status of at least 2 according to the Eastern Cooperative Oncology Group World Health Organization or a Karnofsky score of 50% or greater.~Exclusion Criteria:~* pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential~* severe or underlying chronic illness or disease~* renal insufficiency or liver abnormalities~* chronic use of steroids~* uncontrolled GERD~* current use of proton pump inhibitors~* history of Barrett's esophagus~* history of erosive gastritis~* intolerance to serotonin receptor antagonists~* current use of aprepitant or palonosetron as antiemetics~* concomitant use of H2-receptor antagonists (ranitidine, cimetidine, famotidine or nizatidine) or metaclopramide

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esomeprazole (Type: EXPERIMENTAL): Patients receiving chemotherapy (anthracycline-based) will be randomized to esomeprazole for Cycle 1 Days 1-5 and Cycle 2 Days 1-5
- Sugar pill (Type: PLACEBO_COMPARATOR): Subjects will be given placebo Cycle 1 Days 1-5 and Cycle 2 Days 1-5.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Low Protein Diet in Preventing the Progression of Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Urinary protein excretion 1-10 g/day~* Serum Cr \<2.0 mg/dl~* With diabetic retinopathy \> SDR~* Normal protein intake instruction~* Patients whose consent is obtained at \>20 or age =\<65~Exclusion Criteria:~* Type 1 Diabetes Mellitus~* Non-diabetic nephropathy~* Urinary tract infection~* Congestive heart failure~* Unstable angina~* Myocardial infarction~* Stroke~* Severe hepatopathy~* Life threatening disease such as malignant tumor~* Patients on ACE-I and or ARB treatment~* Patients on instruction of low protein diet~* BW\< 80% of IBW~* Pregnant, lactating, and probably pregnant patients~* Patients judged as being inappropriate fir the subjects

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prenatal Molecular Characterisation by CGH+SNP-ARRAY of Supernumerary Marker Chromosomes and de Novo Apparently Balanced Reciprocal Translocations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metaphase karyotyping with SMC or a de novo Apparently-balanced reciprocal translocation~* Parents covered by the National Health Insurance Agency,~* Consent of the parents~Exclusion Criteria:~* Persons not covered by the National Health Insurance Agency~* Normal foetal karyotyping or showing chromosomal anomalies not related to the present study (trisomy 18....) or inherited anomalies~* Absence of a sample from one of the parents

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-natal Patient (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Round Spermatid Injection Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Major Inclusion Criteria: The following are major inclusion criteria:~1. A diagnosis of azoospermia after semen analysis.~2. Indication to proceed with testicular sperm extraction (TESE or microTESE) based on a urologic evaluation.~3. Presence of round spermatids from testicular sperm extraction (TESE or microTESE), irrespective of the presence or absence of mature spermatozoa.~Major Exclusion Criteria (must not meet any): The following are exclusion criteria:~1. Under 18 years old~2. All patients who do not voluntarily give their written consent for participation.~3. Men who do not wish to use their gametes (round spermatids) for fertilization of donor oocytes for research purposes.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Males undergoing TESE or microTESE (Type: None): All male patients undergoing surgical sperm extraction (TESE or microTESE) procedures as part of an IVF cycle at our center will be reviewed for inclusion and offered participation in the study. These men have been previously consented to the TESE or microTESE procedure at our center. The study will utilize the otherwise discarded round spermatids found in the TESE and microTESE surgical samples as the study samples being used for the ROSI procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Lumbar Spinal Stenosis; Comparison of Two Different Surgical Methods; Mini-invasive Decompression to X-stop

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* neurogenic intermittent claudication due to lumbar spinal stenosis~* diagnosed on MRI in maximum two levels~* walking distance on 250 metres~* symptom relief on flexion of the lumbar spine~* duration of the symptoms more than 6 months~* non-operative treatment is tried or considered as not indicated~Exclusion Criteria:~* vascular claudicatio intermittens~* spinal stenosis on more than 2 levels~* cauda equina syndrome~* severe paresis~* clinical monoradiculopathy~* grave scoliosis~* previous lumbar surgery~* degenerative spondylolisthesis more than 25%~* spondylolysis with listhesis~* osteoporotic fracture in lumbal column~* clinical and radiological (both) arthritis in the hip joint~* ASA \>3~* verified polyneuropathy on neurophysiological test

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- decompression (Type: ACTIVE_COMPARATOR): Minimal invasive decompression
- x-stop (Type: EXPERIMENTAL): X-stop, an interspinous decompression device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* abdominal-thoracic esophagectomy with radical lymphadenectomy~* post operative admission to ICU~* age \>= 18 yrs~* written informed consent~Exclusion Criteria:~* Participation in another interventional trial~* pregnancy or lactation~* systemic medication with high dose steroids and/or immunosuppressants and/or radiotherapy during the last 3 months~* known diseases of the immune system (benign and malign)~* contraindications for extracorporeal therapy~* Thrombocytopenia \< 50\*10\^9/l~* therapy limitations (DNR), moribund status~* missing informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Care (Type: NO_INTERVENTION): intensive care therapy according to international standards and following local SOPs, including fluid therapy, mechanical ventilation, catecholamine therapy and other pharmacotherapy as required
- CytoSorb (Type: EXPERIMENTAL): all of the above, plus extracorporeal hemadsorption therapy (CytoSorbents Adsorber cartridge) using continuous veno-venous hemofiltration (citrate anticoagulation) CytoSorb cytokine elimination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Clinical and Radiographic Results of Pseudarthrosis of Clavicle Treated With Plaque and Screws

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-65 years of pseudarthrosis intervention~2. Males and Females~3. Patients treated for pseudoarthrosis of the clavicle between 2007 and 2017 at the Rizzoli Orthopedic Institute~Exclusion Criteria:~1. Floating shoulder~2. subjects who present contraindications to radiographic examination at the time of telephone contact

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- evaluation of clinical and radiographic findings after surgical treatment (Type: EXPERIMENTAL): Evaluation of clinical and radiographic findings at least 1 year after surgical treatment for pseudoarthrosis of clavicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be willing and able to give informed consent to participate in the trial and to adhere to the procedures stated in the protocol~* ≥18 years of age~* Patient is admitted to a hospital (max. 72 hours prior to randomization) due to COVID-19 and has a positive SARS-CoV-2 PCR test~* Clinical symptoms indicative of moderate or severe illness (corresponding to score 5 or 6 on the WHO 10-point clinical progression scale) with COVID 19 prior to trial treatment~* Patient agrees to not participate in another clinical trial from screening until day 56~Exclusion Criteria:~* Patient is moribund or has an estimated life expectancy \<1 month (e.g., terminal cancer, etc.)~* Patient is anticipated to be discharged from hospital within 48 hours~* Patient requires anti-inflammatory medicines beyond SoC (SoC are drugs that are approved for treatment of COVID-19 as well as medicines that have been recommended in treatment guidelines of national health authorities and/or professional organization)~* Patient requires invasive mechanical ventilation~* Patient is known to have active tuberculosis~* Patient is known to have hereditary fructose intolerance.~* Patient is known to have co-infection with Influenza viruses or other viral respiratory infections (respiratory syncytial virus \[RSV\], parainfluenza viruses, respiratory adenoviruses).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care + Asunercept 100 mg (Type: EXPERIMENTAL): None
- Standard of Care + Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Altered PSA Test Due to Possible Suspected Heterophilic Antibodies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male, with a a clinically high or low unexplainable PSA measurement~* Age between 40 and 90 years~* Written informed consent~Exclusion Criteria:~* Female~* No PSA measurement available or planned~* Age over 90 or under 40 years

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Angiography demonstrating atherosclerosis amenable to treatment by percutaneous coronary intervention (PCI) with or without stent implantation and diagnosis of Acute Coronary Syndrome (ACS) by elevated cardiac markers or ischemic chest discomfort w/electrocardiogram changes + age \> 65 or diabetes.~Exclusion Criteria:~1. Not a candidate for PCI~2. ST-segment elevation myocardial infarction (STEMI) within 48 hours of randomization~3. Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, intra-cranial tumor, cerebral arteriovenous malformation, or intracranial aneurysm; recent (\<1 month) trauma or major surgery \[including coronary artery bypass graft (CABG) surgery\]; currently receiving warfarin, active bleeding~4. Impaired hemostasis: known International Normalized Ratio (INR) \>1.5 at screening; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count \<100,000/µL) at screening~5. Severe hypertension not adequately controlled by antihypertensive therapy at the time of randomization~6. Receipt of fibrinolytic therapy in the 12 hours preceding randomization~7. Receipt of any thienopyridine (clopidogrel or ticlopidine) in the 7 days preceding randomization~8. Glycoprotein IIb/IIIa (GPI) Inhibitor usage within the previous 12 hours \[applicable to unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) patients\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cangrelor (Type: EXPERIMENTAL): cangrelor bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion
- Clopidogrel (Type: ACTIVE_COMPARATOR): placebo bolus \& infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dose-response Study of Carduus Marianus in Centesimal Scale for Dyslipidemia in Climacteric Overweighed or Obese Women.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. women 40-65 years in early or late transition to menopause or postmenopause according to STRAW classification~2. hypertriglyceridemia \[\>150 \<1000 mg/dL\], and/or hypercholesterolemia \[\>200mg/dL\]~3. overweight or obesity \[BMI \>25 Kg/m2\]~4. fasting glucose \<126mg/dL~5. glycosylated hemoglobin \<6.5%~6. be willing and capable to follow study procedures.~Exclusion Criteria:~1. history of cardiovascular disease or coronary risk equivalents~2. secondary hyperlipidemia caused by diabetes mellitus, renal, liver or thyroid diseases~3. hypolipidemic agents, antidiabetic medication, hormone replacement therapy, tamoxifen, raloxifene, danazol, isotretinoin, acitretin, cyclosporin, azathioprine, protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir), antipsychotics (clozapine), seizure medication (carbamazepine, valproic acid, phenobarbital, phenytoin) either on-going or any time in the previous 2 months~4. any other clinically significant illness that, in the opinion of the investigator, might put the patient at risk of harm during the study or might adversely affect the interpretation of the study data~5. pregnancy or breastfeeding.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Diet + exercise + Carduus marianus 6cH (Type: EXPERIMENTAL): Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 6cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
- Diet + exercise + Carduus marianus 12cH (Type: EXPERIMENTAL): Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 12cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
- Diet + exercise + Carduus marianus 30cH (Type: EXPERIMENTAL): Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 30c, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
- Diet + exercise + placebo (Type: PLACEBO_COMPARATOR): Diet (1600 cal/day) + aerobic exercise (30 min daily) + placebo (87°alcohol), 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Evaluation of IRM and Autopsy in the Evaluation of Intra Uterine Fetal Death

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient for which he was diagnosed with intra uterine death confirmed by ultrasound~* Mono fetal pregnancy,~* Term: 24 to 42 weeks' gestation~* Age\> 18 years~* Patient having readen the letter of information and signed the consent.~Exclusion Criteria:~* Contraindication to MRI (heart valve, pacemaker, neurosurgical clips, claustrophobia, intraocular metallic foreign bodies)~* Maternal complications: bleeding during, eclampsia, placental hematoma retro, imminent work~* Twin pregnancy~* Patient under guardianship or trusteeship~* Patient not speaking and writing French

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A group of 20 pregnant patients. (Type: OTHER): 20 patients referred for intrauterine spontaneous fetal death explored by MRI and autopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Foot Controlled Robotic Endoscope Enabled Robot FESS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing FESS surgery for benign pathology~Exclusion Criteria:~* Pregnant/ lactating female patients~* Younger than 18 years of age~* Cognitive impairment or unable to provide informed consent~* Malignant sinus pathologies~* Previous endoscopic sinus surgery~* Contraindication to general anaesthesia~* Untreated active infection~* Non-correctable coagulopathy~* Emergency Surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FREE robot (Type: EXPERIMENTAL): Patients undergoing sinus surgery with the FREE robot

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues